



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/100930/2020

## European Medicines Agency decision

P/0118/2020

of 27 March 2020

on the granting of a product specific waiver for efitlagimod alpha (EMEA-002698-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Only the English text is authentic.**

---

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)

**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



# European Medicines Agency decision

P/0118/2020

of 27 March 2020

on the granting of a product specific waiver for eftilagimod alpha (EMEA-002698-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Immute SAS on 28 October 2019 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 January 2020 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

A waiver for eftilagimod alpha, solution for injection, subcutaneous use, intravenous use, intratumoural use, intraperitoneal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 2**

This decision is addressed to Immutep SAS, Parc Club Orsay, 2, rue Jean Rostand, 91893 - Orsay, France.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/613413/2019  
Amsterdam, 31 January 2020

## Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-002698-PIP01-19

### Scope of the application

**Active substance(s):**

Eftilagimod alpha

**Condition(s):**

Treatment of breast cancer

**Pharmaceutical form(s):**

Solution for injection

**Route(s) of administration:**

Subcutaneous use

Intravenous use

Intratumoural use

Intraperitoneal use

**Name/corporate name of the PIP applicant:**

Immutep SAS

### Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Immutep SAS submitted to the European Medicines Agency on 28 October 2019 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 3 December 2019.



## Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
  - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

## **Annex I**

### **Grounds for the granting of the waiver**

# 1. Waiver

## **1.1. Condition:**

Treatment of breast cancer

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- solution for injection, subcutaneous use, intravenous use, intratumoural use, intraperitoneal use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).